Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Mayo Clinic Proceedings|August 11, 1991
Systemic adjuvant therapy in women with resected node-negative breast cancerL C Hartmann, R F Marschke, D J Schaid, et al.
Mayo Clinic Proceedings|July 1, 1981
Etiologic considerations in superior vena cava syndromeJ M Parish, R F Marschke, D E Dines, et al.
International Journal of Radiation Oncology, Biology, Physics|January 15, 1994
Prospective phase I evaluation of radiation therapy, 5-fluorouracil, and levamisole in locally advanced gastrointestinal cancerJ A Martenson, A J Schutt, G L Grado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1984
A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancerE T Creagan, S J Green, D L Ahmann, et al.
American Journal of Clinical Oncology|October 1, 1988
Evaluation of fludarabine phosphate in patients with recurrent gliomaT L Cascino, L D Brown, R F Morton, et al.
Medical and Pediatric Oncology|January 1, 1988
Phase II study of bisantrene administered by continuous 72-hour infusion for advanced pancreatic adenocarcinomaR F Marschke, L K Kvols, S A Cullinan, et al.
American Journal of Clinical Oncology|February 1, 1997
Evaluation of intravenous 6-thioguanine as first-line chemotherapy in women with metastatic breast cancerJ N Ingle, D I Twito, V J Suman, et al.
American Journal of Clinical Oncology|November 5, 1997
Phase II study of combined levamisole with recombinant interleukin-2 in patients with advanced malignant melanomaE T Creagan, K M Rowland, V J Suman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trialT E Witzig, L Letendre, J Gerstner, et al.
Cancer|April 1, 1996
Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinomaJ T Schleusener, H D Tazelaar, S H Jung, et al.
Pageof 3